Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Inclusion Criteria: * Histologically or cytologically confirmed newly diagnosed ER-/HER2- breast cancer. ER and PR \< Allred score of 3 or \< 1% positive staining cells in the invasive component of the tumor. HER2 negative by FISH or IHC staining 0 or 1+ according to NCCN guidelines. * Clinical stage II or III (by AJCC 8th edition at least T2, any N, M0 or if N+ then any T) breast cancer eligible for neoadjuvant chemotherapy with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal. * Tumor size at least 2 cm in one dimension by clinical or radiographic exam (WHO criteria). Patients with histologically confirmed or clinically palpable lymph nodes may be enrolled regardless of tumor size. A palpable mass is not required as long as the mass is at least 2 cm in one dimension by radiographic exam. 2D measurements should be completed during screening if available. * No prior therapy for this disease * At least 18 years of age. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 * Normal bone marrow and organ function as defined below: * Leukocytes ≥ 2,000/mcL (stable off any growth factor within 4 weeks of first study treatment administration) * Absolute neutrophil count ≥ 1,500/mcL (stable off any growth factor within 4 weeks of first study treatment administration) * Platelets ≥ 100,000/mcL (stable off any growth factor within 4 weeks of first study treatment administration) * Hemoglobin ≥8.5 g/dl (transfusion t…